文献速递贫血与红细胞疾病

直接抗病毒药物治疗血红蛋白病患者丙型肝炎病毒感染安全有效

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
PubMed 文献 · Am J Hematol · 2017-10-19

这项观察性研究评估直接抗病毒药物(DAAs)在139例意大利血红蛋白病合并慢性HCV感染及晚期肝纤维化患者中的安全性和有效性,12周持续病毒学应答率为93.5%,与无血红蛋白病的肝硬化患者相当,且血清铁蛋白显著降低。

要点

  • 139例血红蛋白病患者接受DAAs治疗,12周持续病毒学应答率为93.5%。
  • 3例患者观察期间死亡,死因与DAAs无关;1例无病毒学应答,5例(3.6%)在治疗后12周随访内复发。
  • 治疗后12周血清铁蛋白显著降低,水平与39例无HCV感染且坚持螯合治疗的重型地中海贫血对照组相似。

核心结论

  • 在血红蛋白病合并HCV所致晚期肝病患者中,使用DAAs似乎是安全有效的。

研究设计与样本

  • 观察性研究,纳入意大利血红蛋白病合并慢性HCV感染及晚期肝纤维化患者139例,2015年3月至2016年12月接受DAAs治疗并完成治疗结束后12周随访以评估持续病毒学应答(12SVR)。

主要发现

  • 12SVR率为93.5%,与无血红蛋白病的肝硬化患者中通常观察到的应答率相当。
  • 观察期间3例患者死亡,死因与DAAs无关。
  • 1例患者未达到病毒学应答,5例(3.6%)在治疗结束后12周随访内复发。
  • 患者治疗后12周血清铁蛋白显著降低,水平与39例无HCV感染、坚持螯合治疗且无明显铁过载的重型地中海贫血对照组相似。

关键数值与推荐

  • 欧洲肝脏研究学会指南推荐对血红蛋白病患者的HCV感染采用无干扰素方案治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow-up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Origa R, Ponti ML, Filosa A, et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol. 2017. PMID: 28929515. doi:10.1002/ajh.24911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。